Puripharm

Puripharm is a clinical-stage biopharmaceutical company headquartered in Shanghai, China, specializing in the development of innovative topical therapies for inflammatory skin diseases and autoimmune disorders. The company's primary focus is on leveraging its expertise in medicinal chemistry and topical drug delivery to create highly effective and safe treatments for conditions such as atopic dermatitis, psoriasis, and alopecia areata. Its lead candidate, P005, is a potent topical Janus kinase (JAK) inhibitor currently undergoing clinical trials to evaluate its efficacy and safety profile compared to existing standards of care. Puripharm aims to address significant unmet medical needs in dermatology through its targeted pipeline of small molecule inhibitors. By focusing on topical administration, the company seeks to minimize systemic side effects while maximizing local therapeutic impact for patients.